Propanc Biopharma Inc. (PPCB)
NASDAQ: PPCBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PPCB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.87M
- EPS (TTM)
- -$95.92
- Dividend yield
- None
- 52-week range
- 1.61 – 315.00
- Day range
- 1.77 – 2.00
- Volume / Avg
- 27.83K / 188.66K
- Beta
- —
- Shares outstanding
- 1.05M
52-week range
PPCB stock today
On Nov 20, PPCB ended the session at $1.78, adding $0.055 (3.19%), versus the S&P 500's 3.70% decline. Trading was light, with 27.83K shares changing hands, about 15% of the average daily volume. Shares are 99.4% below their 52-week high of $315.00 and 10.6% above the 52-week low of $1.61, near the bottom of the past year's range.
Propanc Biopharma has posted a net loss over the last twelve months (EPS of -$95.92), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Propanc Biopharma
Company profilePropanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. James Nathanielsz
- Headquarters
- Camberwell, VIC
- Employees
- 2
- Website
- propanc.com
Financial highlights
Full financialsPropanc Biopharma reported a net loss of $18.9 million, compared with a loss of $58.9 million a year earlier. Diluted earnings per share came in at -$17.62.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-18.86M | $-58.92M | $-1.82M | $-2.66M | $-2.66M |
| EPS (diluted) | $-17.62 | $-371.22 | $-1,420.53 | $-1.80 | $-49.23 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-12.22 vs —
PPCB news
All PPCB news- Propanc Reports PRP Activity In Pancreatic Cancer Models, Files Combination Patent ApplicationNasdaqPPCB, UHAL.B
- Propanc Biopharma, Inc. Receives Nasdaq Delisting Notice Over $1.00 Minimum Bid Price RequirementNasdaqPPCB, WSO.B
- Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer PatientsGlobeNewswire
- Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer PatientsGlobeNewswire
- Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic VulnerabilityGlobeNewswire
- CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth PlansGlobeNewswire
- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth PlansGlobeNewswire
- Propanc Reports Preclinical Data For PRP In Chemoresistance; Phase 1 Set For Q1 '27NasdaqPPCB, BRK.A
Propanc Biopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SBFMSunshine Biopharma Inc. | 2.23 | -5.11% | $1.84M | vs PPCB |
| PPBTPurple Biotech Ltd. ADR | 1.53 | -4.09% | $1.86M | vs PPCB |
| XRTXXORTX Therapeutics Inc. | 0.839 | -5.73% | $1.88M | vs PPCB |
| EOCNEocene Ltd. | 1.78 | +1.73% | $1.90M | vs PPCB |
| KALAKALA BIO Inc. | 2.71 | -10.28% | $1.74M | vs PPCB |
| GNPXGenprex Inc. | 1.45 | -13.17% | $1.94M | vs PPCB |
| DCOYDecoy Therapeutics Inc. | 0.8294 | -4.68% | $1.98M | vs PPCB |
| REVBRevelation Biosciences Inc. | 3.50 | -5.15% | $1.99M | vs PPCB |
Indexes, lists and sector
Propanc Biopharma stock FAQ
What is Propanc Biopharma's stock price today?
PPCB last traded at $1.78 as of Nov 20, 4:00 PM EST, up 3.19% on the day. Prices are delayed at least 15 minutes.
Does Propanc Biopharma pay a dividend?
No. Propanc Biopharma does not currently pay a regular cash dividend.
Who is Propanc Biopharma's CEO?
Mr. James Nathanielsz is the chief executive officer of Propanc Biopharma Inc., which has about 2 employees.
Has PPCB ever split its stock?
Yes. The most recent PPCB stock split was a 1-for-10 split on Oct 26, 2026.
What is the PPCB 52-week high?
The 52-week high for PPCB is $315.00 and the 52-week low is $1.61. The stock is currently 99.4% below its high.